NYSE:USNAUSANA Health Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding USANA Health Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $84.12 -0.47 (-0.56 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$83.97Now: $84.12▼$86.1850-Day Range$66.91MA: $78.96▼$89.2252-Week Range$43.01Now: $84.12▼$90.94Volume18,347 shsAverage Volume253,503 shsMarket Capitalization$1.77 billionP/E Ratio18.13Dividend YieldN/ABeta0.94 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensébeautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 1.3 Analyst's Opinion Consensus RatingUSANA Health Sciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.00, USANA Health Sciences has a potential downside of 17.4% from its current price of $84.75.Amount of Analyst CoverageUSANA Health Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesUSANA Health Sciences has received 357 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUSANA Health Sciences has received 447 “underperform” votes. (Add your “underperform” vote.)Community SentimentUSANA Health Sciences has received 55.60% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about USANA Health Sciences and other stocks. Vote “Outperform” if you believe USNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe USNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUSANA Health Sciences does not currently pay a dividend.Dividend GrowthUSANA Health Sciences does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, USANA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,967,499.00 in company stock.Percentage Held by Insiders45.40% of the stock of USANA Health Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.31% of the stock of USANA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for USANA Health Sciences are expected to grow by 5.89% in the coming year, from $4.75 to $5.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of USANA Health Sciences is 18.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.01.Price to Earnings Ratio vs. SectorThe P/E ratio of USANA Health Sciences is 18.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.45.Price to Book Value per Share RatioUSANA Health Sciences has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.34 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Medicinals & botanicals Sub-IndustryPersonal Products SectorMedical Current SymbolNYSE:USNA Previous Symbol CUSIP90328M10 CIK896264 Webwww.usana.com Phone801-954-7100Debt Debt-to-Equity RatioN/A Current Ratio2.30 Quick Ratio1.82Price-To-Earnings Trailing P/E Ratio18.13 Forward P/E Ratio17.71 P/E GrowthN/A Sales & Book Value Annual Sales$1.06 billion Price / Sales1.67 Cash Flow$5.74 per share Price / Cash Flow14.65 Book Value$15.11 per share Price / Book5.57Profitability EPS (Most Recent Fiscal Year)$4.41 Net Income$100.53 million Net Margins9.76% Return on Equity30.09% Return on Assets20.73%Miscellaneous Employees1,909 Outstanding Shares21,010,000Market Cap$1.77 billion Next Earnings Date7/28/2020 (Estimated) OptionableOptionable USNA Rates by TradingView Receive USNA News and Ratings via Email Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter. USANA Health Sciences (NYSE:USNA) Frequently Asked Questions How has USANA Health Sciences' stock been impacted by COVID-19 (Coronavirus)? USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, USNA shares have increased by 21.3% and is now trading at $84.75. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of USANA Health Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for USANA Health Sciences. When is USANA Health Sciences' next earnings date? USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for USANA Health Sciences. How were USANA Health Sciences' earnings last quarter? USANA Health Sciences, Inc. (NYSE:USNA) released its quarterly earnings data on Tuesday, April, 21st. The company reported $1.23 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.57 by $0.66. The firm had revenue of $266.62 million for the quarter, compared to the consensus estimate of $220.40 million. USANA Health Sciences had a net margin of 9.76% and a return on equity of 30.09%. The firm's revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.01 EPS. View USANA Health Sciences' earnings history. How will USANA Health Sciences' stock buyback program work? USANA Health Sciences declared that its Board of Directors has authorized a share repurchase program on Wednesday, February 5th 2020, which authorizes the company to repurchase $130,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 9.1% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued. What guidance has USANA Health Sciences issued on next quarter's earnings? USANA Health Sciences issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, April, 21st. The company provided earnings per share guidance of 4.00-4.90 for the period, compared to the Thomson Reuters consensus estimate of $4.01. The company issued revenue guidance of $1-1.08 billion, compared to the consensus revenue estimate of $1.01 billion. What price target have analysts set for USNA? 4 analysts have issued 12-month price objectives for USANA Health Sciences' stock. Their forecasts range from $65.00 to $75.00. On average, they anticipate USANA Health Sciences' share price to reach $70.00 in the next year. This suggests that the stock has a possible downside of 17.4%. View analysts' price targets for USANA Health Sciences. What are Wall Street analysts saying about USANA Health Sciences stock? Here are some recent quotes from research analysts about USANA Health Sciences stock: 1. According to Zacks Investment Research, "USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company's three primary product lines consist of nutritional, personal care and weight management products. The company's products are distributed primarily through a network marketing system. " (5/3/2020) 2. Pivotal Research analysts commented, "We thought it noteworthy that the company projected average diluted shares outstanding of 22.7 million, given that 2Q diluted shares out were 23.4 million. To get to that average we expect the company will need to buy-in 1.9 million shares in the 2H. That will put average shares outstanding down 7.7% for the year. This is not so important for 2019, but it will be for next year when we see an earnings recovery of 27% at the net income line (still below 2018) but EPS growth of 38% owing to the reduced share count." (7/24/2019) Has USANA Health Sciences been receiving favorable news coverage? Press coverage about USNA stock has been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. USANA Health Sciences earned a news impact score of -3.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutUSANA Health Sciences. Are investors shorting USANA Health Sciences? USANA Health Sciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 1,570,000 shares, a decrease of 16.0% from the April 30th total of 1,870,000 shares. Based on an average daily trading volume, of 268,900 shares, the short-interest ratio is currently 5.8 days. Approximately 13.0% of the shares of the stock are sold short. View USANA Health Sciences' Current Options Chain. Who are some of USANA Health Sciences' key competitors? Some companies that are related to USANA Health Sciences include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Prestige Consumer Healthcare (PBH), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR). View all competitors. What other stocks do shareholders of USANA Health Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include IBM (IBM), Gilead Sciences (GILD), AT&T (T), Allergan (AGN), AbbVie (ABBV), Amgen (AMGN), Intel (INTC), Intuitive Surgical (ISRG), NVIDIA (NVDA) and Tesla (TSLA). Who are USANA Health Sciences' key executives? USANA Health Sciences' management team includes the following people: Dr. Myron W. Wentz, Founder & Chairman (Age 78)Mr. Kevin G. Guest, CEO & Director (Age 56)Mr. Jim Brown, Pres & COO (Age 50)Mr. G. Douglas Hekking, Chief Financial Officer (Age 49)Mr. Walter Noot, Chief Information Officer (Age 53) What is USANA Health Sciences' stock symbol? USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA." Who are USANA Health Sciences' major shareholders? USANA Health Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.02%), Acadian Asset Management LLC (3.68%), State Street Corp (2.01%), Morgan Stanley (1.05%), Morgan Stanley (1.05%) and Geode Capital Management LLC (1.04%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Robert Auciaux and Walter Noot. View institutional ownership trends for USANA Health Sciences. Which major investors are selling USANA Health Sciences stock? USNA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, BlackRock Inc., JPMorgan Chase & Co., MERIAN GLOBAL INVESTORS UK Ltd, Martingale Asset Management L P, Parametric Portfolio Associates LLC, and Aigen Investment Management LP. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert Auciaux, and Walter Noot. View insider buying and selling activity for USANA Health Sciences. Which major investors are buying USANA Health Sciences stock? USNA stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Morgan Stanley, Morgan Stanley, Mackay Shields LLC, and Bogle Investment Management L P DE. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull, and Myron W Wentz. View insider buying and selling activity for USANA Health Sciences. How do I buy shares of USANA Health Sciences? Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is USANA Health Sciences' stock price today? One share of USNA stock can currently be purchased for approximately $84.75. How big of a company is USANA Health Sciences? USANA Health Sciences has a market capitalization of $1.78 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis. USANA Health Sciences employs 1,909 workers across the globe. What is USANA Health Sciences' official website? The official website for USANA Health Sciences is www.usana.com. How can I contact USANA Health Sciences? USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
